Physician profile
Paul Mansour
NPI 1982863122
$2,460.41
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $429 · 2021: $370 · 2022: $354 · 2023: $784 · 2024: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.76 | 2020-2024 | Lifevest |
| Inari Medical, INC. | $299.20 | 2020-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Vifor Pharma, INC. | $284.43 | 2020-2023 | Veltassa |
| Pfizer INC. | $191.93 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $166.12 | 2022-2023 | |
| Abbott Laboratories | $140.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $129.00 | 2019-2023 | Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.40 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $98.05 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $88.47 | 2021-2023 | Nuzyra |
| Melinta Therapeutics, LLC | $84.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $55.82 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $47.98 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $44.38 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $40.59 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.47 | 2021 | |
| Portola Pharmaceuticals, LLC | $34.63 | 2020 | |
| Boston Scientific Corporation | $34.30 | 2024 | Watchman Flx |
| Aurinia Pharma U.S., INC. | $29.31 | 2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Astellas Pharma US INC | $21.32 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.27 | 2020 | |
| Bioxcel Therapeutics, INC. | $21.16 | 2023 | Igalmi |
| Allergan, INC. | $19.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.50 | 2020 | |
| Fisher & Paykel Healthcare INC | $17.83 | 2023 | Fisher & Paykel Healthcare |
| Dexcom, INC. | $16.37 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.